Price movement over the last 24 hours
Alcon AG vs NEOS S&P 500 High Income ETF — how do they compare? Alcon AG trades at $66.97 (market cap $32.69B), while NEOS S&P 500 High Income ETF trades at $53.05. The key difference: Alcon AG pays a 0.54% dividend while NEOS S&P 500 High Income ETF pays none, and NEOS S&P 500 High Income ETF is trading nearer its 52-week high, Alcon AG nearer its low. Which is the better fit depends on your goals.
| ALC | SPYI | |
|---|---|---|
Market Cap | $32.69B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $92.22 | $54.07 |
52-Week Low | $62.02 | $47.98 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
SPYI trades at $53.45, up 0.74% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF has surpassed $10 billion in assets under management, driven by strong demand for its covered-call strategy that delivers an 11.86% yield. Recent dividends of $0.52-$0.54 per share highlight its income focus, though key valuation ratios like P/E and P/B are not applicable for this ETF structure.
Outlook remains positive due to robust investor inflows and competitive yield advantages over peers like JEPI. Risks include high fees impacting long-term returns and potential volatility from its options strategy. The fund's tax-efficient distributions appeal to retirees, but reliance on return of capital requires careful monitoring.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →